- Home
- RYAM vs CRVS Comparison
RYAM vs CRVS Comparison
Compare RYAM & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYAM
- CRVS
- Stock Information
- Founded
- RYAM 1926
- CRVS 2014
- Country
- RYAM United States
- CRVS United States
- Employees
- RYAM N/A
- CRVS N/A
- Industry
- RYAM Paper
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- RYAM Basic Materials
- CRVS Health Care
- Exchange
- RYAM Nasdaq
- CRVS Nasdaq
- Market Cap
- RYAM 255.7M
- CRVS 305.4M
- IPO Year
- RYAM N/A
- CRVS 2016
- Fundamental
- Price
- RYAM $4.31
- CRVS $4.71
- Analyst Decision
- RYAM Buy
- CRVS Strong Buy
- Analyst Count
- RYAM 1
- CRVS 4
- Target Price
- RYAM $6.00
- CRVS $15.00
- AVG Volume (30 Days)
- RYAM 504.6K
- CRVS 918.4K
- Earning Date
- RYAM 08-05-2025
- CRVS 08-05-2025
- Dividend Yield
- RYAM N/A
- CRVS N/A
- EPS Growth
- RYAM N/A
- CRVS N/A
- EPS
- RYAM N/A
- CRVS N/A
- Revenue
- RYAM $1,598,619,000.00
- CRVS N/A
- Revenue This Year
- RYAM N/A
- CRVS N/A
- Revenue Next Year
- RYAM $3.23
- CRVS N/A
- P/E Ratio
- RYAM N/A
- CRVS N/A
- Revenue Growth
- RYAM 2.20
- CRVS N/A
- 52 Week Low
- RYAM $3.45
- CRVS $2.13
- 52 Week High
- RYAM $10.28
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- RYAM 56.14
- CRVS 63.53
- Support Level
- RYAM $4.07
- CRVS $4.10
- Resistance Level
- RYAM $4.52
- CRVS $4.98
- Average True Range (ATR)
- RYAM 0.17
- CRVS 0.21
- MACD
- RYAM 0.01
- CRVS 0.05
- Stochastic Oscillator
- RYAM 47.06
- CRVS 76.23
About RYAM Rayonier Advanced Materials Inc.
Rayonier Advanced Materials Inc is engaged in the production of cellulose specialties, a natural polymer used in the manufacturing of various specialty chemical products, including liquid crystal displays, filters, textiles and performance additives for pharmaceutical, food and other industrial applications. The company's products are used in a variety of applications, including cigarette filters, liquid crystal displays, paints, pharmaceuticals, and food. The company operates in the reportable segments of High Purity Cellulose, Paperboard, and High-Yield Pulp. The key revenue is derived from the High Purity Cellulose segment. Geographically, it derives a majority of its revenue from the United States.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).